1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Authors: Jay B. Varkey1, Bruce S. Ribner2
  • Editors: W. Michael Scheld3, James M. Hughes4, Richard J. Whitley5
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Emory University School of Medicine, Atlanta, GA 30307; 2: Emory University School of Medicine, Atlanta, GA 30307; 3: Department of Infectious Diseases, University of Virginia Health System, Charlottesville, VA; 4: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA; 5: Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL
  • Source: microbiolspec May 2016 vol. 4 no. 3 doi:10.1128/microbiolspec.EI10-0011-2016
  • Received 11 January 2016 Accepted 19 January 2016 Published 27 May 2016
  • Jay B. Varkey, jay.varkey@emory.edu
image of Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/4/3/EI10-0011-2016-1.gif /docserver/preview/fulltext/microbiolspec/4/3/EI10-0011-2016-2.gif
  • Abstract:

    Ending the West Africa Ebola virus disease (EVD) outbreak required an unprecedented international response. For the United States, participation in the international response to the West Africa EVD outbreak provided an opportunity to learn important lessons in four key domains critical to preparing for future outbreaks of EVD and other serious communicable diseases: (i) safe and effective patient care, (ii) the role of experimental therapeutics and vaccines, (iii) infection control, and (iv) hospital and community preparedness.

  • Citation: Varkey J, Ribner B. 2016. Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. Microbiol Spectrum 4(3):EI10-0011-2016. doi:10.1128/microbiolspec.EI10-0011-2016.

Key Concept Ranking

Severe Acute Respiratory Syndrome
0.45685124
Ebola Virus
0.44948286
0.45685124

References

1. World Health Organization. 2015. Origins of the 2014 Ebola Epidemic: One Year Into the Ebola Epidemic. http://www.who.int/csr/disease/ebola/one-year-report/virus-origin/en/.
2. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S. 2014. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371:1418–1425. [PubMed][CrossRef]
3. Centers for Disease Control and Prevention. 2016. Outbreaks Chronology: Ebola Virus Disease. http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html.
4. World Health Organization. 2016. Ebola Situation Report: 30 December 2015. http://apps.who.int/ebola/current-situation/ebola-situation-report-30-december-2015.
5. Fowler RA, Fletcher T, Fischer WA II, Lamontagne F, Jacob S, Brett-Major D, Lawler JV, Jacquerioz FA, Houlihan C, O’Dempsey T, Ferri M, Adachi T, Lamah MC, Bah EI, Mayet T, Schieffelin J, McLellan SL, Senga M, Kato Y, Clement C, Mardel S, Vallenas Bejar De Villar RC, Shindo N, Bausch D. 2014. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med 190:733–737. [PubMed][CrossRef]
6. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, Shindo N, Fischer WA II, Lamontagne F, Saliou SM, Bausch DG, Moumié B, Jagatic T, Sprecher A, Lawler JV, Mayet T, Jacquerioz FA, Méndez Baggi MF, Vallenas C, Clement C, Mardel S, Faye O, Faye O, Soropogui B, Magassouba N, Koivogui L, Pinto R, Fowler RA. 2015. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 372:40–47. [PubMed][CrossRef]
7. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, Sealfon RS, Kanneh L, Moigboi A, Momoh M, Fullah M, Moses LM, Brown BL, Andersen KG, Winnicki S, Schaffner SF, Park DJ, Yozwiak NL, Jiang PP, Kargbo D, Jalloh S, Fonnie M, Sinnah V, French I, Kovoma A, Kamara FK, Tucker V, Konuwa E, Sellu J, Mustapha I, Foday M, Yillah M, Kanneh F, Saffa S, Massally JL, Boisen ML, Branco LM, Vandi MA, Grant DS, Happi C, Gevao SM, Fletcher TE, Fowler RA, Bausch DG, Sabeti PC, Khan SH, Garry RF, KGH Lassa Fever Program, Viral Hemorrhagic Fever Consortium, WHO Clinical Response Team. 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371:2092–2100. [PubMed][CrossRef]
8. Rollin PE, Bausch DG, Sanchez A. 2007. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 196(Suppl 2):S364–S371. [PubMed][CrossRef]
9. Uyeki TM, Mehta AK, Davey RT, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grünewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AIM, Gutman J, Working Group of the U.S.-European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe. 2016. Clinical management of Ebola virus disease patients in the U.S. and Europe. N Engl J Med 374:636–646. [PubMed][CrossRef]
10. Connor MJ, Jr, Kraft C, Mehta AK, Varkey JB, Lyon GM, Crozier I, Ströher U, Ribner BS, Franch HA. 2015. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol 26:31–37. [PubMed][CrossRef]
11. Sueblinvong V, Johnson DW, Weinstein GL, Connor MJ, Jr, Crozier I, Liddell AM, Franch HA, Wall BR, Kalil AC, Feldman M, Lisco SJ, Sevransky JE. 2015. Critical care for multiple organ failure secondary to Ebola virus disease in the United States. Crit Care Med 43:2066–2075. [PubMed][CrossRef]
12. Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, Eller MA, Eller LA, Michael NL, Honko AN, Olinger GG, Jr, Schoepp RJ, Hepburn MJ, Hensley LE, Robb ML. 2015. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 15:905–912. [CrossRef]
13. Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D, Muyembe-Tamfum JJ, Bwaka MA, De Roo A, Colebunders R. 1999. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis 179(Suppl 1):S13–S14. [PubMed][CrossRef]
14. Trenchard T. 2014. Survivors cope with new Ebola after-effects. Al-Jazeera. http://www.aljazeera.com/news/africa/2014/12/survivors-cope-with-new-ebola-after-effects-2014121573521561384.html.
15. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, Kumar G, Smith JR, Kainulainen MH, Whitmer S, Ströher U, Uyeki TM, Ribner BS, Yeh S. 2015. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 372:2423–2427. [PubMed][CrossRef]
16. Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T, Christie A, Schroth GP, Gross SM, Davies-Wayne GJ, Shinde SA, Murugan R, Sieh SB, Badio M, Fakoli L, Taweh F, de Wit E, van Doremalen N, Munster VJ, Pettitt J, Prieto K, Humrighouse BW, Ströher U, DiClaro JW, Hensley LE, Schoepp RJ, Safronetz D, Fair J, Kuhn JH, Blackley DJ, Laney AS, Williams DE, Lo T, Gasasira A, Nichol ST, Formenty P, Kateh FN, De Cock KM, Bolay F, Sanchez-Lockhart M, Palacios G. 2015. Molecular evidence of sexual transmission of Ebola virus. N Engl J Med 373:2448–2454. [PubMed][CrossRef]
17. Fink S. 2015. Ebola survivor from Scotland is critically ill. New York Times. http://www.nytimes.com/2015/10/15/world/europe/scottish-nurse-who-had-ebola-is-back-in-hospital-and-critically-ill.html.
18. World Health Organization. 2014. Potential Ebola Therapies and Vaccines: Interim Guidance. http://www.who.int/csr/resources/publications/ebola/potential-therapies-vaccines/en/.
19. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM III, Friedman-Moraco RJ, Marconi VC, Hill CE, Sullivan JN, Johnson DW, Lisco SJ, Mulligan MJ, Uyeki TM, McElroy AK, Sealy T, Campbell S, Spiropoulou C, Ströher U, Crozier I, Sacra R, Connor MJ, Jr, Sueblinvong V, Franch HA, Smith PW, Ribner BS, Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. 2015. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 61:496–502. [PubMed][CrossRef]
20. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, Lyon GM, Ribner BS, Varkey J, Sidney J, Sette A, Campbell S, Ströher U, Damon I, Nichol ST, Spiropoulou CF, Ahmed R. 2015. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci USA 112:4719–4724. [PubMed][CrossRef]
21. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ, International Scientific and Technical Committee. 1999. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 179(Suppl 1):S18–S23. [PubMed][CrossRef]
22. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. 2012. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109:5034–5039. [PubMed][CrossRef]
23. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. 2007. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 196(Suppl 2):S400–S403. [PubMed][CrossRef]
24. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53. [PubMed][CrossRef]
25. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, Kraft CS, Towner JS, Spiropoulou C, Ströher U, Uyeki TM, Ribner BS, Emory Serious Communicable Diseases Unit. 2014. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 371:2402–2409. [PubMed][CrossRef]
26. Wong G, Qiu X. 2015. Development of experimental and early investigational drugs for the treatment of Ebola virus infections. Expert Opin Investig Drugs 24:999–1011. [PubMed][CrossRef]
27. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375:1896–1905. [PubMed][CrossRef]
28. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I. 2006. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193:1650–1657. [PubMed][CrossRef]
29. Pollack A. 2015. Clinical trial of experimental Ebola drug is halted. New York Times. http://www.nytimes.com/2015/06/20/health/clinical-trial-of-experimental-ebola-drug-is-halted.html?_r=0.
30. Sissoko D, Folkesson E, Abdoul M, Beavogi AH, Gunther S, Shepherd S, Danel C, Mentre F, Anglaret X, Malvy D. 2015. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. Abstract 103-ALB. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA.
31. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7:393–400. [PubMed][CrossRef]
32. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. 2002. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8:503–507. [PubMed][CrossRef]
33. Reynard O, Mokhonov V, Mokhonova E, Leung J, Page A, Mateo M, Pyankova O, Georges-Courbot MC, Raoul H, Khromykh AA, Volchkov VE. 2011. Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J Infect Dis 204(Suppl 3):S1060–S1065. [PubMed][CrossRef]
34. Hoenen T, Groseth A, Feldmann H. 2012. Current ebola vaccines. Expert Opin Biol Ther 12:859–872. [PubMed][CrossRef]
35. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Ströher U, Feldmann H, Jones SM. 2009. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 4:e5547. doi:10.1371/journal.pone.0005547. [CrossRef]
36. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. 2015. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe: preliminary report. N Engl J Med. [Epub ahead of print.] doi:10.1056/NEJMoa1502924. [PubMed][CrossRef]
37. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, Kéïta S, Kieny MP, Røttingen JA. 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:857–866. [PubMed][CrossRef]
38. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA, Nabel GJ. 2011. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 17:1128–1131. [PubMed][CrossRef]
39. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS, VRC 205 Study Team. 2010. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29:304–313. [PubMed][CrossRef]
40. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Nichol ST, Ksiazek TG, Rollin PE. 2007. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196(Suppl 2):S142–S147. [PubMed][CrossRef]
41. Centers for Disease Control and Prevention. 2014. Hospital preparedness: a tiered approach. http://www.cdc.gov/vhf/ebola/healthcare-us/preparing/treatment-centers.html. [PubMed]
42. Smith PW, Anderson AO, Christopher GW, Cieslak TJ, Devreede GJ, Fosdick GA, Greiner CB, Hauser JM, Hinrichs SH, Huebner KD, Iwen PC, Jourdan DR, Kortepeter MG, Landon VP, Lenaghan PA, Leopold RE, Marklund LA, Martin JW, Medcalf SJ, Mussack RJ, Neal RH, Ribner BS, Richmond JY, Rogge C, Daly LA, Roselle GA, Rupp ME, Sambol AR, Schaefer JE, Sibley J, Streifel AJ, Essen SG, Warfield KL. 2006. Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement. Biosecur Bioterror 4:351–365. [PubMed][CrossRef]
43. Hewlett AL, Varkey JB, Smith PW, Ribner BS. 2015. Ebola virus disease: preparedness and infection control lessons learned from two biocontainment units. Curr Opin Infect Dis 28:343–348. [PubMed][CrossRef]
44. Feistritzer NR, Hill C, Vanairsdale S, Gentry J. 2014. Care of patients with Ebola virus disease. J Contin Educ Nurs 45:479–481. [PubMed][CrossRef]
45. Schwedhelm S, Beam EL, Morris RD, Sebastian JG. 2015. Reflections on interprofessional team-based clinical care in the ebola epidemic: the Nebraska Medicine experience. Nurs Outlook 63:27–29. [PubMed][CrossRef]
46. Centers for Disease Control and Prevention. 2015. Guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation (PUIs) for Ebola who are clinically unstable or have bleeding, vomiting, or diarrhea in U.S. hospitals, including procedures for donning and doffing PPE. http://www.cdc.gov/vhf/ebola/healthcare-us/ppe/guidance.html.
47. MacIntyre CR, Chughtai AA, Seale H, Richards GA, Davidson PM. 2015. Uncertainty, risk analysis and change for Ebola personal protective equipment guidelines. Int J Nurs Stud 52:899–903. [PubMed][CrossRef]
48. Iwen PC, Smith PW, Hewlett AL, Kratochvil CJ, Lisco SJ, Sullivan JN, Gibbs SG, Lowe JJ, Fey PD, Herrera VL, Sambol AR, Wisecarver JL, Hinrichs SH. 2015. Safety considerations in the laboratory testing of specimens suspected or known to contain Ebola virus. Am J Clin Pathol 143:4–5. [PubMed][CrossRef]
49. Centers for Disease Control and Prevention. 2015. Guidance for U.S. laboratories for managing and testing routine clinical specimens when there is a concern about Ebola virus disease. http://www.cdc.gov/vhf/ebola/healthcare-us/laboratories/safe-specimen-management.html.
50. American Society for Microbiology. 2014. Interim laboratory guidelines for handling/testing specimens from cases or suspected cases of hemorrhagic fever virus (HFV). https://www.asm.org/images/PSAB/Ebola9-10-14.pdf.
51. Hill CE, Burd EM, Kraft CS, Ryan EL, Duncan A, Winkler AM, Cardella JC, Ritchie JC, Parslow TG. 2014. Laboratory test support for Ebola patients within a high-containment facility. Lab Med 45:e109–e111. [PubMed][CrossRef]
52. Centers for Disease Control and Prevention. 2014. Procedures for safe handling and management of Ebola-associated waste. http://www.cdc.gov/vhf/ebola/healthcare-us/cleaning/handling-waste.html.
53. Centers for Disease Control and Prevention. 2015. Interim guidance for environmental infection control in hospitals for Ebola virus. http://www.cdc.gov/vhf/ebola/healthcare-us/cleaning/hospitals.html.
54. United States Environmental Protection Agency. 2015. List L: Disinfectants for use against the Ebola virus. http://www.epa.gov/pesticide-registration/list-l-disinfectants-use-against-ebola-virus.
55. Lowe JJ, Olinger PL, Gibbs SG, Rengarajan K, Beam EL, Boulter KC, Schwedhelm MM, Hayes AK, Kratochvil CJ, Vanairsdale S, Frislie B, Lewis J, Hewlett AL, Smith PW, Gartland B, Ribner BS. 2015. Environmental infection control considerations for Ebola. Am J Infect Control 43:747–749. [PubMed][CrossRef]
56. Gates B. 2015. The next epidemic: lessons from Ebola. N Engl J Med 372:1381–1384. [PubMed][CrossRef]
57. Dzau VJ, Rodin J. 2015. Creating a global health risk framework. N Engl J Med 373:991–993. [PubMed][CrossRef]
58. World Health Organization. 2015. Report of the Ebola interim assessment panel. http://www.who.int/csr/resources/publications/ebola/ebola-interim-assessment/en/.
59. World Health Organization. 2015. Factors that contributed to undetected spread of the Ebola virus and impeded rapid containment. http://www.who.int/csr/disease/ebola/one-year-report/factors/en/.
60. National Academy of Medicine. 2016. Global health risk framework. http://nam.edu/initiatives/global-health-risk-framework/.
61. World Health Organization. 2015. WHO Secretariat response to the report of the Ebola interim assessment panel. http://www.who.int/csr/resources/publications/ebola/who-response-to-ebola-report.pdf.
62. Wayne A. 2014. Congress nearly grants Obama’s Ebola wish list with $5.4B. Bloomberg. http://www.bloomberg.com/news/articles/2014-12-10/congress-nearly-grants-obama-s-ebola-wish-list-with-5-4b.
63. U.S. Department of Health & Human Services. 2015. HHS invests in enhancing domestic preparedness efforts for Ebola. http://www.hhs.gov/about/news/2015/02/20/hhs-invests-in-enhancing-domestic-preparedness-efforts-for-ebola.html.
microbiolspec.EI10-0011-2016.citations
cm/4/3
content/journal/microbiolspec/10.1128/microbiolspec.EI10-0011-2016
Loading

Citations loading...

Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.EI10-0011-2016
2016-05-27
2017-11-18

Abstract:

Ending the West Africa Ebola virus disease (EVD) outbreak required an unprecedented international response. For the United States, participation in the international response to the West Africa EVD outbreak provided an opportunity to learn important lessons in four key domains critical to preparing for future outbreaks of EVD and other serious communicable diseases: (i) safe and effective patient care, (ii) the role of experimental therapeutics and vaccines, (iii) infection control, and (iv) hospital and community preparedness.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Schematic of the Serious Communicable Diseases Unit (SCDU), Emory University Hospital.

Source: microbiolspec May 2016 vol. 4 no. 3 doi:10.1128/microbiolspec.EI10-0011-2016
Permissions and Reprints Request Permissions
Download as Powerpoint

Tables

Generic image for table
TABLE 1

Factors contributing to 2013–2015 Ebola outbreak ( 58 , 59 )

Source: microbiolspec May 2016 vol. 4 no. 3 doi:10.1128/microbiolspec.EI10-0011-2016
Generic image for table
TABLE 2

WHO’s agenda for change ( 61 )

Source: microbiolspec May 2016 vol. 4 no. 3 doi:10.1128/microbiolspec.EI10-0011-2016
Generic image for table
TABLE 3

Emergency medical services and emergency department preparedness

Source: microbiolspec May 2016 vol. 4 no. 3 doi:10.1128/microbiolspec.EI10-0011-2016

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error